170 related articles for article (PubMed ID: 21110024)
1. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
[TBL] [Abstract][Full Text] [Related]
2. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
4. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
Cancer Biol Ther; 2010 Jul; 10(1):99-107. PubMed ID: 20495354
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
6. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
7. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
Schwarz RE; Konduri S; Awasthi N; Cafasso D; Schwarz MA
Surgery; 2009 Aug; 146(2):241-9. PubMed ID: 19628080
[TBL] [Abstract][Full Text] [Related]
8. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
[TBL] [Abstract][Full Text] [Related]
9. Cooperative antitumor effect of endothelial-monocyte activating polypeptide II and flutamide on human prostate cancer xenografts.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI; Grygorenko VN
Exp Oncol; 2011 Dec; 33(4):231-4. PubMed ID: 22217713
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
11. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
13. Additive effect of low-frequency ultrasound and endothelial monocyte-activating polypeptide II on blood-tumor barrier in rats with brain glioma.
Zhang Z; Xue Y; Liu Y; Shang X
Neurosci Lett; 2010 Aug; 481(1):21-5. PubMed ID: 20600613
[TBL] [Abstract][Full Text] [Related]
14. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II.
Schwarz RE; Schwarz MA
J Surg Res; 2004 Jul; 120(1):64-72. PubMed ID: 15172191
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
16. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
[TBL] [Abstract][Full Text] [Related]
17. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
Kayton ML; Libutti SK
Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
[TBL] [Abstract][Full Text] [Related]
18. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress.
Barnett G; Jakobsen AM; Tas M; Rice K; Carmichael J; Murray JC
Cancer Res; 2000 Jun; 60(11):2850-7. PubMed ID: 10850427
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
[TBL] [Abstract][Full Text] [Related]
20. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
